Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander hoofdstuk

2010 | OriginalPaper | Hoofdstuk

18. Antilichaamtherapie bij het syndroom van Sjögren

Auteurs: J. M. Meijer, P. M. Meiners, Dr. H. Bootsma, Prof. dr. A. Vissink

Gepubliceerd in: Het Tandheelkundig Jaar 2010

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Het syndroom van Sjögren (SS) komt wereldwijd voor. De prevalentie van SS wordt geschat op 0,5-1% van de bevolking. Deze hoge prevalentie maakt SS, op reumatoïde artritis (RA) na, tot de meest voorkomende reumatologische aandoening. SS kan primair en secundair voorkomen. Primair SS wordt gekenmerkt door de combinatie van droge ogen, droge mond en vaak ook een zwelling van de speekselklieren. Bij secundair SS is naast deze trias sprake van een tweede auto-immuun gerelateerde aandoening, zoals RA of systemische lupus erythematodes (SLE). In iets meer dan de helft van de gevallen is er sprake van secundair SS. De ziekte komt vaker voor bij vrouwen dan bij mannen, in de verhouding 9 : 1 en openbaart zich over het algemeen tussen het 20ste en 40ste levensjaar (Fox, 2005).
Literatuur
go back to reference Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J et al. Reduction of fatigue in Sjogren’s syndrome with rituximab: results of a randomised, double-blind, placebo controlled pilot study. Ann Rheum Dis 2008;67(11):1541–4. PubMedCrossRef Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J et al. Reduction of fatigue in Sjogren’s syndrome with rituximab: results of a randomised, double-blind, placebo controlled pilot study. Ann Rheum Dis 2008;67(11):1541–4. PubMedCrossRef
go back to reference Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S et al. Improvement of Sjogren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007;57(2):310–7. PubMedCrossRef Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S et al. Improvement of Sjogren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007;57(2):310–7. PubMedCrossRef
go back to reference Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64(6):913–20. PubMedCrossRef Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64(6):913–20. PubMedCrossRef
go back to reference Hansen A, Lipsky PE, Dorner T. Immunopathogenesis of primary Sjogren’s syndrome: implications for disease management and therapy. Curr Opin Rheumatol 2005;17(5):558-65. PubMedCrossRef Hansen A, Lipsky PE, Dorner T. Immunopathogenesis of primary Sjogren’s syndrome: implications for disease management and therapy. Curr Opin Rheumatol 2005;17(5):558-65. PubMedCrossRef
go back to reference Kalk WW, Mansour K, Vissink A, Spijkervet FK, Bootsma H, Kallenberg CG et al. Oral and ocular manifestations in Sjogren’s syndrome. J Rheumatol 2002;29(5):924-30. PubMed Kalk WW, Mansour K, Vissink A, Spijkervet FK, Bootsma H, Kallenberg CG et al. Oral and ocular manifestations in Sjogren’s syndrome. J Rheumatol 2002;29(5):924-30. PubMed
go back to reference Meijer JM, Meiners PM, Huddleston Slater JJR, Spijkervet FK, Kallenberg CG, Vissink A et al. Health related quality of life, employment and disability in patients with Sjögren’s syndrome. Rheumatology (Oxford) 2009;48(9):1077–82. CrossRef Meijer JM, Meiners PM, Huddleston Slater JJR, Spijkervet FK, Kallenberg CG, Vissink A et al. Health related quality of life, employment and disability in patients with Sjögren’s syndrome. Rheumatology (Oxford) 2009;48(9):1077–82. CrossRef
go back to reference Meijer JM, Pijpe J, Bootsma H, Vissink A, Kallenberg CG. The future of biologic agents in the treatment of Sjogren’s syndrome. Clin Rev Allergy Immunol 2007;32(3):292–7. PubMedCrossRef Meijer JM, Pijpe J, Bootsma H, Vissink A, Kallenberg CG. The future of biologic agents in the treatment of Sjogren’s syndrome. Clin Rev Allergy Immunol 2007;32(3):292–7. PubMedCrossRef
go back to reference Meijer JM, Pijpe J, Imhoff GW van, Vissink A, Spijkervet FK, Mansour K et al. Retreatment with rituximab in patients with active primary Sjögren’s syndrome. IXth International Symposium on Sjogren’s Syndrome. Abstract. 2006. Meijer JM, Pijpe J, Imhoff GW van, Vissink A, Spijkervet FK, Mansour K et al. Retreatment with rituximab in patients with active primary Sjögren’s syndrome. IXth International Symposium on Sjogren’s Syndrome. Abstract. 2006.
go back to reference Pijpe J, Kalk WWI, Wal JE van der, Vissink A, Kluin PM, Roodenburg JLN et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjögren’s syndrome. Rheumatology (Oxford) 2007;46(2):335-41. CrossRef Pijpe J, Kalk WWI, Wal JE van der, Vissink A, Kluin PM, Roodenburg JLN et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjögren’s syndrome. Rheumatology (Oxford) 2007;46(2):335-41. CrossRef
go back to reference Pijpe J, Imhoff GW van, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K et al. Rituximab treatment in patients with primary Sjogren’s syndrome: An open-label phase II study. Arthritis Rheum 2005;52(9):2740-50. PubMedCrossRef Pijpe J, Imhoff GW van, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K et al. Rituximab treatment in patients with primary Sjogren’s syndrome: An open-label phase II study. Arthritis Rheum 2005;52(9):2740-50. PubMedCrossRef
go back to reference Seror R, Sordet C, Gottenberg JE, Guillevin L, Masson C, Sibilia J et al. Good tolerance and efficacy of rituximab on systemic features in 12 patients with primary Sjögren’s syndrome. Abstract. Arthritis Rheum 2005;52(9 Suppl). Seror R, Sordet C, Gottenberg JE, Guillevin L, Masson C, Sibilia J et al. Good tolerance and efficacy of rituximab on systemic features in 12 patients with primary Sjögren’s syndrome. Abstract. Arthritis Rheum 2005;52(9 Suppl).
go back to reference Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al. Classifieation criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61(6):554–8. PubMedCrossRef Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al. Classifieation criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61(6):554–8. PubMedCrossRef
go back to reference Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjogren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren’s Syndrome. Arthritis Rheum 1999;42(8):1765-72. PubMedCrossRef Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjogren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren’s Syndrome. Arthritis Rheum 1999;42(8):1765-72. PubMedCrossRef
Metagegevens
Titel
Antilichaamtherapie bij het syndroom van Sjögren
Auteurs
J. M. Meijer
P. M. Meiners
Dr. H. Bootsma
Prof. dr. A. Vissink
Copyright
2010
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-7510-3_18